Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223424 · ClinicalTrials.gov registry record · Phase 2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Diwakar Davar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
- 1
- Study location
NCT07223424 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Diwakar Davar. The registered enrollment target is 480 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07223424, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Diwakar Davar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG nivolumab
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2030-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223424
The ClinicalTrials.gov registry entry for NCT07223424 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (27% lower). The listed sponsor is Diwakar Davar, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT07223424 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07223424 about?
NCT07223424 is a clinical study titled "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy". The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
What is the current status of trial NCT07223424?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2025-11-04. Estimated completion is 2030-11-30.
What conditions does trial NCT07223424 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Cervical Cancer, Hepatocellular Carcinoma, Esophageal Cancer.
What interventions are being tested in trial NCT07223424?
The interventions under investigation include: pembrolizumab (DRUG), nivolumab (DRUG).
Who is sponsoring clinical trial NCT07223424?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223424 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.